Kalina Duncan

Kalina Duncan

Auto-generated profile, based on publicly available information

Kalina Duncan

Center for Global Health, National Cancer Institute, National Institutes of Health, Rockville, Maryland

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Substance Use & Misuse
Verified
Journal Article
Closed access
ADAnita Das
Anita Das
EOElizabeth Orlan
Elizabeth Orlan
KDKalina Duncan
Kalina Duncan
HTHeather Thomas
Heather Thomas
ANAmara Ndumele
Amara Ndumele
MPMark Parascandola
Mark Parascandola
Background: Areca nut (AN) and betel quid (BQ) are classified as Group 1 carcinogens. There are approximately 600 million AN/BQ users globally; the majority of users live in the Asia-Pacific region which, correspondingly, has the highest rates of oral cancer. Despite significant disease burden associated with AN/BQ use, there have been no systematic reviews of interventions to reduce product use. Objectives: To analyze interventions that prevent use of AN/BQ, present a basis for a future systematic review on the topic, and provide decision makers with examples of strategies that have demonstrated reduced AN/BQ use. Methods: To identify publications, we searched the literature using terms for AN/BQ and related synonyms in three databases: PubMed, Embase, and Scopus. Interventions that prevent AN/BQ use, that are published in English and that provide original data analysis, were included in this review. Interventions focused primarily on disease outcomes e.g. oral cancers (secondary prevention) were excluded. Results: Our search revealed 21 interventions targeting AN/BQ use between 1990 and 2018. Strategies include product bans, media campaigns, education, cessation, and taxation at individual and population levels, with varying evidence of impact. While these studies yielded some novel and promising findings, particularly regarding the impact of product bans, mass media campaigns, and cessation interventions, research on interventions specific to AN/BQ use remains limited. Conclusions: We have assessed published interventions that reduce AN/BQ use and identified future research priorities. These findings can be used to develop evidence-based interventions and help guide policymakers in implementing evidence-based policy to regulate these products.

22 June 2020 in Journal of Cancer Policy
Verified
Journal Article
Closed access
MCM.K. Cira
M.K. Cira
RTR. Tesfay
R. Tesfay
JZJ.A. Zujewski
J.A. Zujewski
DSD.T. Sinulingga
D.T. Sinulingga
SAS. Aung
S. Aung
ADA. Dvaladze
A. Dvaladze

1 December 2019 in Journal of Global Oncology
Verified
Journal Article
Open access
AVAmanda L. Vogel
Amanda L. Vogel
JFJordan A. Freeman
Jordan A. Freeman
KDKalina Duncan
Kalina Duncan
JAJames Alaro
James Alaro
JWJohn J. Welch
John J. Welch
MWMakeda J. Williams
Makeda J. Williams
PURPOSE: The burden of cancer in Africa is growing rapidly, and increased cancer research on the continent is a critical component of an effective response. In 2010, the US National Cancer Institute, in partnership with the African Organization for Research and Training in Cancer, launched the Beginning Investigator Grant for Catalytic Research (BIG Cat) initiative to support cancer research projects conducted by early-career African investigators. METHODS: To date, BIG Cat has provided 18 awards of up to $50,000 to support 2-year cancer research projects. In 2017, the National Cancer Institute evaluated BIG Cat’s early outcomes for cancer research and impacts on career development and local cancer research capacity. Data collection consisted of a review of project documentation and a survey fielded to the 12 investigators who had completed their BIG Cat awards. RESULTS: BIG Cat–supported research projects have generated locally relevant findings that address a range of cancer sites and multiple areas of scientific interest. The 11 survey respondents produced 43 scholarly products (e.g., publications, presentations) about findings from their BIG Cat research. They reported increases in cancer research funding applications and awards after receipt of the BIG Cat award compared with before the award. They also reported increased resources for cancer research, participation in teaching and mentoring on cancer research, and supervision of cancer research staff. Investigators identified scientific mentoring as a key facilitator of the success of their BIG Cat projects and limited time and funding as key challenges. CONCLUSION: Findings provide early evidence that BIG Cat advanced locally relevant cancer research and facilitated career advancement and development of local cancer research capacity. Findings have implications for the design of future related efforts.

1 December 2025 in Journal of Cancer Policy
Verified
Journal Article
Open access
LELinsey Eldridge
Linsey Eldridge
ACAmina Chtourou
Amina Chtourou
KDKalina Duncan
Kalina Duncan
LGLeslie Given
Leslie Given
SHSana Haider
Sana Haider
MCMishka Kohli Cira
Mishka Kohli Cira
As cancer incidence in low- and middle-income countries (LMICs) continues to rise, the development of National Cancer Control Plans (NCCP) has become an essential policy tool for guiding a comprehensive and coordinated response. The NCCP Development Research Initiative (NCCP DRIVE) is a qualitative study led by the International Cancer Control Partnership (ICCP) to understand the NCCP development process and contextual factors that may enable or impede effective NCCP development. In-depth interviews were conducted with country-level cancer planners in nine countries (seven African, two South Asian) within the ICCP network. Transcripts were recorded, transcribed, and double-coded in Dedoose, then analyzed thematically using the Health Policy Triangle (HPT) framework. Findings highlight that NCCP development is dynamic and iterative, following six commonly reported phases: Initiation, Formulation, Negotiation, Communication, Implementation, and Monitoring/Evaluation. Common challenges reported by respondents included limited financial and human resources, competing priorities, fragmented health systems, and inadequate data. These constraints led to compressed timelines, overlapping planning activities, and gaps in costing and implementation plans. To address these challenges, respondents employed various strategies, including integrating cancer control efforts with existing health programs, engaging multisector actors, building political will, and securing technical assistance (TA) from partners. Building partnerships was pivotal, helping to set priorities, align plans with national and global agendas, and leverage resources. However, some respondents reported misaligned timelines and priorities, and coordination challenges. This study contributes a policy framework-informed, implementation-focused analysis of NCCP development, offering practical insights into how countries navigate complex challenges to initiate and sustain cancer control planning. Findings underscore the need for flexible TA models and stronger data systems, and the value of integrating cancer control priorities within existing health systems. Understanding these dynamics from initiation to implementation offers practical insights for countries at various stages of development, and for partners providing technical assistance.

28 April 2025 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
ALAnisha M. Loeb
Anisha M. Loeb
PGPatti Gravitt
Patti Gravitt
AFAllison Frank
Allison Frank
DPDouglas M. Puricelli Perin
Douglas M. Puricelli Perin
KDKalina Duncan
Kalina Duncan
PAPrajakta Adsul
Prajakta Adsul
The COVID-19 pandemic disrupted many public health programs; understanding these disruptions is critical for directing future resources. In a project studying the implementation of human papillomavirus (HPV) testing-based cervical cancer screening, we queried about the impact of the pandemic on screening programs globally. In consultation with World Health Organization’s Regional Advisors, program managers, government officials, and clinicians involved in the implementation of HPV testing-based cervical cancer screening programs were invited to participate in semi-structured, in-depth, interviews. Interview notes and transcripts were used for inductive analysis, focusing on responses to the impact of COVID-19 pandemic on screening programs. Thirty-two interviews were conducted with participants between the age of 29 and 61 years, representing programs from 25 countries. Six key themes were noted. Regarding disruptions, (1) the entire cancer continuum was affected, leading to delays or, in some cases even cessation of vaccination, screening, and treatment programs; and (2) a heightened sense of fear around contracting and transmitting COVID-19 shifted government priorities and impacted healthcare delivery. Nonetheless, participants noted constructive ways in which programs leveraged the impact of the pandemic: (1) at the community level, participants were able to leverage an increased understanding and acceptance surrounding the importance of preventive health behaviors; (2) for HPV-testing: molecular laboratories became well-equipped with better technician training, increasing overall HPV-testing capacities; (3) the pandemic promoted virtual healthcare systems; and (4) for planning: shutdowns allowed time to plan for program scale-up. In many ways, the pandemic response provided evidence supporting countries’ abilities to mobilize resources. While disruptions were noted, the pandemic provided implementers with opportunities to strengthen screening programs, which should be further assessed in future sustainability research on cervical cancer prevention and control.

1 December 2025 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
LELinsey Eldridge
Linsey Eldridge
MBMaría T. Bourlon
María T. Bourlon
ECEduardo Cazap
Eduardo Cazap
ACAmina Chtourou
Amina Chtourou
KDKalina Duncan
Kalina Duncan
MCMishka Kohli Cira
Mishka Kohli Cira
We are pleased to present the accepted abstracts from the 13th Annual Symposium on Global Cancer Research (ASGCR). The 2025 symposium highlights both the commitment and growth of the global oncology community, marking 5 years since ASGCR’s transition to a fully virtual format. What began as a pandemic-driven necessity has evolved into a deliberate strategy to broaden participation and minimize barriers. Over this period, ASGCR has expanded its reach, expanded its content, and strengthened global collaboration through initiatives such as requiring low- and middle-income country coauthorship, launching the Early Career Investigator Day, and adopting open calls for scientific session proposals.